Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School discusses the results of the NETTER-1 study, which concluded with patients who were treated with octreotide had significantly improved progression free survival compared to patients who were not treated with the drug. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.
NETTER-1 and Octreotide for Advanced Small Bowel Carcinoids
